OncoHost Collaborates with Henlius USA to Identify Resistance Patterns in Small Cell Lung Cancer Patients
OncoHost, a leading technology company in precision medicine, has announced a collaboration with Henlius USA, the U.S. specialty division of Shanghai Henlius Biotech, Inc. The collaboration aims to identify and characterize potential resistance patterns in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) through the use of OncoHost’s innovative PROphet® platform.
The comprehensive Phase III clinical trial, conducted by Henlius USA, is evaluating the efficacy and safety of Serplulimab combined with chemotherapy (carboplatin – etoposide) in previously untreated ES-SCLC patients in the United States. By utilizing OncoHost’s PROphet® platform, Henlius USA aims to identify correlative biomarkers that can provide valuable insights into patient response and resistance mechanisms.
PROphet® combines bioinformatics, system biology, proteomic pattern recognition, and machine learning to predict the probability of clinical benefit in response to immunotherapy. By analyzing 7,000 proteins in patient blood samples using aptamer-based assays, the platform can provide valuable information for patient selection, overall survival/progression-free survival prediction, mechanisms of action discovery, adverse events prediction, and response prediction.
The collaboration between OncoHost and Henlius USA aims to enhance the understanding of resistance mechanisms and personalize care for cancer patients. By identifying potential proteomics-based biomarkers, the study aims to provide additional insights into patient response to the targeted combination therapy, ultimately improving patient outcomes.
Ofer Sharon, CEO of OncoHost, expressed his excitement about the collaboration, stating, “We stand at the height of a transformative era in cancer therapeutics, and we are honored to support Henlius USA in better understanding resistance mechanisms to truly personalize care. Our shared goal is to improve cancer patients’ outcomes by developing robust, scientifically sound technologies to support them and their caregivers.”
Henlius USA, a subsidiary of Henlius, is a global biopharmaceutical company focused on providing high-quality, affordable, and innovative biologic medicines for patients worldwide. With a strong emphasis on oncology, autoimmune diseases, and ophthalmic diseases, Henlius USA aims to bring new hope to those affected by these challenging conditions.
The collaboration between OncoHost and Henlius USA represents a significant step forward in precision medicine. By leveraging the power of proteomic pattern recognition and machine learning, this partnership has the potential to revolutionize the approach to cancer treatment and improve patient outcomes.
For more information about Henlius USA, please visit http://www.henlius.com/en/index.html. To learn more about OncoHost and its PROphet® platform, visit www.oncohost.com.
Contact:
Lior Alperovich
Marcom Manager, OncoHost
lior@oncohost.com
+972-54-282-4503